Background: Pharmacogenomic profiling is an attractive strategy for individualizing chemotherapy. Several genetic polymorphisms predict the survival of patients with non-small cell lung cancer treated with platinum-based chemotherapy. This phase II clinical trial was performed using a non-platinum-based chemotherapy doublet. The impact of previously identified polymorphisms on clinical outcomes was assessed. Methods: Patients with advanced non-small cell lung cancer who had not received previous chemotherapy were treated with docetaxel 40 mg/m 2 on days 1 and 8 and gemcitabine 800 mg/m 2 days 1 and 8 every 21 days until disease progression or unacceptable toxicity. A pretreatment blood sample was obtained, and genomic DNA was analyzed for polymorphisms in DNA repair and metabolic genes. Results: Forty-nine patients were enrolled and evaluated for response and survival. The overall radiographic response rate was 38%, and the median survival was 8.6 months. Nonhematologic toxicity was generally mild. Two treatment related deaths occurred: one due to neutropenic sepsis during the first cycle and one due to pulmonary edema after 12 cycles of treatment. Polymorphisms in XPD, XRCC1, and XRCC3 did not significantly predict survival, but trends similar to those reported for platinum-based chemotherapy were observed. The wild-type XPD genotype was associated with prolonged survival and a significantly higher risk of grade 4 neutropenia (p ϭ 0.02). Conclusion: This regimen of docetaxel and gemcitabine is well tolerated and active for the treatment of advanced non-small cell lung cancer. The impact of XPD polymorphisms on hematologic toxicity is similar to what has been reported for platinum-based chemotherapy.
N on-small cell lung cancers vary in biological aggressiveness and chemotherapy sensitivity. When administered to an unselected population, several chemotherapy regimens produce similar improvements in survival. [1] [2] [3] [4] [5] Individualizing chemotherapy is an attractive strategy for improving outcomes. 6 Polymorphisms in DNA repair genes alter chemotherapy sensitivity and can be measured using peripheral blood, making them attractive for clinical testing. 6 -11 Options for frontline chemotherapy include platinumbased and non-platinum-based chemotherapy doublets. 12 Non-platinum-based chemotherapy doublets, including docetaxel and gemcitabine, have demonstrated similar survival benefits compared with platinum-based doublets in randomized phase III clinical trials. 4, 5 These combinations represent a reasonable option for frontline treatment but are generally reserved for patients with contraindications to platinum such as renal insufficiency. Polymorphisms in certain DNA repair genes including XPD, XRCC1, and XRCC3 have been reported to predict the survival of patients treated with platinum-based chemotherapy. [7] [8] [9] [10] [11] These polymorphisms may be useful markers of resistance to platinum-containing regimens. However, it is also possible that these polymorphisms predict biological aggressiveness independent of the treatment administered.
The current phase II clinical trial was performed to assess the safety and activity of a non-platinum-based chemotherapy doublet, gemcitabine, and docetaxel. Polymorphisms in XPD, XRCC1, XRCC3, and other genes were assessed to determine whether these would predict clinical outcomes for this nonplatinum-based chemotherapy regimen.
MATERIALS AND METHODS

Patient Eligibility
Patients were required to have stage IIIB with malignant effusion or stage IV non-small cell lung cancer. Patients who had relapsed after initial surgery or radiation therapy were eligible provided they had not received previous chemotherapy. Patients with brain metastases were eligible 2 weeks after completing radiation therapy. All patients were required to have a documented histopathologic or cytopathologic diagnosis. Patients were also required to have measurable disease and Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were ineligible if they had received previous chemotherapy, had inadequate organ function, were pregnant or breast-feeding, or were currently receiving radiation therapy. Adequate organ function was defined as absolute neutrophil count Ͼ1500/L; platelet count Ͼ100,000/l; creatinine two times or less the upper limit of normal (ULN); normal bilirubin; and adequate liver enzyme levels, which were defined as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 2.5 times or less the ULN with a normal alkaline phosphatase; alkaline phosphatase four times or less the ULN with normal AST and ALT; or AST and ALT Յ1.5 times or less the ULN and alkaline phosphatase 2.5 times of less the ULN.
Study Design
This study was approved by the Institutional Review Board of Wake Forest University and the Protocol Review Committee of the Comprehensive Cancer Center of Wake Forest University. After obtaining written informed consent, patients were treated with gemcitabine 800 mg/m 2 followed by docetaxel 40 mg/m 2 with both drugs given intravenously on days 1 and 8 every 3 weeks. This dose and schedule were selected based on results of a phase I clinical trial that found this regimen to be well tolerated and active. 13 Treatment was continued until unacceptable toxicity or disease progression. Gemcitabine was mixed in 250 ml of normal saline and administered over 30 minutes. Docetaxel was mixed in an appropriate volume of normal saline or D5W and administered over 30 minutes immediately after gemcitabine. Required premedication consisted of dexamethasone 8 mg orally 12 hours before, 1 hour before, and 12 hours after docetaxel administration. Optional premedications included 5-HT 3 antagonists, diphenhydramine, and H 2 blockers. Prophylactic granulocyte growth factor support was not administered with the first cycle but could be given with subsequent cycles.
Toxicity and Response Assessment
Physical examination and routine laboratory tests were performed before each cycle of chemotherapy. Complete blood counts were performed weekly for the first two cycles and then before each treatment for the remaining cycles. National Cancer Institute Common Toxicity Criteria version 2.0 was used for grading toxicity. Doses were reduced by 25% for febrile neutropenia, grade 4 neutropenia for Ն7 days, or platelet count Յ100,000. Docetaxel doses were held for abnormal liver function with total bilirubin more than the ULN, alkaline phosphatase more than five times the ULN, or AST more than five times the ULN. Doses were held for nonhematologic toxicities grade 3 or higher with doses restarted once toxicity improved to grade 2. In the case of pulmonary toxicity grade 3 or higher or anaphylaxis, treatment was permanently discontinued.
Tumor measurements were performed before initiation of treatment and then every two cycles until disease progression or unacceptable toxicity. Tumor response was assessed using Response Evaluation Criteria in Solid Tumors. 14 
Genotyping Procedure
Blood samples were obtained before treatment. DNA was extracted from the samples using Qiagen's QiAamp DNA Blood Mini Kit (Valencia, CA). Gene polymorphisms in drug metabolic and DNA repair enzymes were determined by polymerase chain reaction-restriction fragment length polymorphism (CYP1A1, 15 CYP3A5, 16 GSTP1 105, XRCC1, 17 XRCC3, 17 and XPD) or polymerase chain reaction-single-stranded conformational polymorphism (GSTP1 114) using the primers and conditions listed in Table 1 . Standard PCR conditions for all genes were as follows: initial denaturation at 95°C followed by 40 cycles of denaturation at 95°C for 30 seconds, extension at 72°C for 1 minute, and a final extension at 72°C for 7 minutes. Specific annealing temperatures and times as well as restriction digestion enzymes are listed in Table 1 . The numbering of CYP1A1 base pair changes listed in Table 1 has been updated in accordance with currently accepted nomenclature.
For determination of GSTP1 114 variants, DNA was amplified and analyzed by SSCP using Amersham's Gene-Phor System. Precast GeneGel Clean 15/24 acrylamide gel was rehydrated in Buffer B according to the manufacturer's instructions and polymerase chain reaction product was denatured at 95°C for 5 minutes in a 99% formamide buffer containing 0.04% bromophenol blue and 0.05% xylene cyanol and then immediately placed on ice. Six microliters of the sample was loaded onto the gel and electrophoresed at 13°C for 15 minutes at 170 V, 10 mA, 5 W, then 45 minutes at 310 V, 15 mA, 5 W, and finally 15 minutes at 380 V, 15 mA, 5 W. The wild-type and variant alleles were distinguishable through the specific banding patterns observed on the gel after staining with the Plus One DNA Silver Staining Kit (Amersham BioSciences, Piscataway, NJ.).
Statistical Methods
The sample size was selected based on having 90% power to demonstrate a 20% improvement in an expected response rate of 30% using a two-stage Simon design. The first stage was designed to include 22 patients with the study being stopped and the null hypothesis accepted if seven or fewer patients responded to therapy. Survival, progressionfree survival, and toxicity statistics were performed on an intent-to-treat basis. Survival and time to progression were assessed using the Kaplan-Meier method. Comparisons of survival curves were performed using the log-rank test. Correlations of genotype with clinical outcomes were performed using the Fisher exact test. All p values shown are two sided. Statistical significance was defined as a two-sided p value Ͻ0.05.
status of 2. The patient characteristics are displayed in Table  2 . The majority of the patients had Eastern Cooperative Oncology Group performance status of 1 and stage IV disease. Other patient demographics were within the expected range for a population of patients with advanced non-small cell lung cancer.
Response and Survival
At the time of analysis, the median duration of follow-up was 262 days. The median survival was 8.6 months and the median progression-free survival was 4.0 months, displayed in Figure 1 . The 1-and 3-year survival probabilities were 37% and 18%, respectively.
Four patients were not assessable for radiographic response. One patient was ineligible due to performance status, and three patients died without evidence of progression before completing two cycles. One died of neutropenic sepsis due to treatment, one died of a pulmonary embolism due to cancer, and one died of a probable intracerebral hemorrhage due to cancer.
Of the 45 patients assessable for radiographic response, changes in tumor measurements were partial response in 17 (38%), stable disease in 17 (38%), and progressive disease in 11 (24%). This did not meet the predefined endpoint of a greater than 39% response rate.
Toxicity
All patients were assessable for toxicity. Nonhematologic toxicity was generally mild. Grade 3 and 4 nonhematologic toxicities considered at least possibly related to treatment are displayed in Table 3 . Two treatment-related deaths occurred. One patient died of neutropenic sepsis during the first cycle of treatment. Another patient died of progressive pulmonary edema after receiving 12 cycles of treatment.
Hematologic toxicity is summarized in Table 4 . Grade 3 or 4 hematologic toxicity occurred in 24 (49%) patients. Grade 4 neutropenia occurred in seven (14%) patients. Febrile neutropenia occurred in only one patient who subsequently died of neutropenic sepsis. 
Dose Intensity
The planned dose intensity was 27 mg/m 2 per week for docetaxel and 533 mg/m 2 per week for gemcitabine. Eight patients (16%) required a dose reduction during the course of therapy. The percentage of the total planned chemotherapy dose actually delivered to patients was 97%.
Pharmacogenomic Analyses
Genotyping was performed on blood samples obtained from 36 patients who were assessable for survival and toxicity. Thirty-three were also assessable for response. Toxicities were examined and compared for patients with wild-type genotype or harboring one or two variant alleles ( Table 5 ). Neutropenia was more severe in patients with a wild-type XPD genotype. Grade 4 neutropenia occurred in five of 13 (38%) wild-type cases and only one of 23 (4%) variant cases (p ϭ 0.02).
None of the examined polymorphisms significantly correlated with response rate or median survival. Polymorphisms in XPD, XRCC1 399, and XRCC3 had previously been reported to predict survival for patients treated with platinum-based chemotherapy. Although the median survival values were not significantly different, 2-year survival trends similar to those observed for platinum-based chemotherapy were observed for XPD, XRCC1 399, and XRCC3. The 2-year survival probability for all patients was 18%. Patients with a homozygous variant XPD or XRCC1 399 genotype tended to have a shorter survival with none of these patients alive at 2 years compared with a 2-year survival of 22% (95% confidence interval [CI]: 11%-43%) for patients with at least one wild-type XPD allele and 23% (95% CI, 11%-47%) for patients with at least one wild-type XRCC1 399 allele. Patients with a homozygous variant XRCC3 genotype tended to have a longer survival with 50% (95% CI: 22%-100%) of patients harboring this genotype alive at 2 years compared with a 2-year survival of 13% (95% CI: 5%-33%) for patients with at least one wild-type XRCC3 allele.
DISCUSSION
Cytotoxic chemotherapy continues to be the mainstay for initial treatment of patients with advanced non-small cell lung cancer. Individualizing chemotherapy to deliver the most active agent to each patient could provide an important advance. 6 Previous studies have identified pharmacogenomic predictors of survival for patients with advanced non-small cell lung cancer treated with platinum-based chemotherapy. [7] [8] [9] [10] [11] Among these are the XRCC1, XRCC3, and XPD genes. Each of these genes plays an important role in the repair of DNA damage. 18 -25 Similar to previous studies of platinum-based chemotherapy, we identified a trend toward decreased survival for patients with variant XPD or XRCC1 genotype and increased survival for patients with variant XRCC3 genotype. Based on these findings, it is not clear that these three polymorphisms will prove useful for choosing between platinum-or non-platinum-based combination chemotherapy for initial treatment.
Our findings suggest that the XPD variant genotype confers resistance to this nonplatinum chemotherapy in the bone marrow and the tumor. Patients with homozygous variant XPD genotype experienced both poorer survival and a lower rate of neutropenia. These two effects of XPD polymorphisms have been observed in previous studies using platinum-based chemotherapy. [7] [8] [9] 11 Finding differences in neutropenia indicate that XPD polymorphisms alter chemotherapy sensitivity and do not simply mark the biological aggressiveness of the tumor.
Determining how XPD polymorphisms confer resistance to cytotoxic chemotherapy could provide an important advance. [21] [22] [23] 25 XPD is one of nine subunits in the general transcription factor TIIF. XPD has dual functions in the cell: nucleotide excision repair and cell cycle regulation through regulation of Cdk-activating kinase. 25, 26 Perhaps by understanding how XPD functions, new agents targeting XPD could be developed to overcome chemotherapy resistance. It is also possible that targeted agents, alone or in combination, will play a particularly important role for the treatment of the population of patients harboring a variant XPD genotype. 27, 28 In the current study, we used peripheral blood to assess the germ line genotype but did not directly genotype tumor tissue. It is possible that deletions of one allele could occur during lung carcinogenesis and render cancers functionally homozygous despite arising from a heterozygous germ line population. If so, tumor tissue genotyping could enhance the predictive value of these polymorphisms. This question should be studied in future work.
Non-platinum-based chemotherapy doublets combining several agents including docetaxel, gemcitabine, paclitaxel, vinorelbine, and irinotecan at various doses and schedules have been reported. 4,5,29 -34 The dose and schedule of docetaxel and gemcitabine used in this study are associated with an acceptable rate of toxicity and a median survival within the expected range. This regimen is a reasonable option for the treatment of patients with advanced non-small cell lung cancer, particularly those with contraindications to platinum-based chemotherapy.
A similar dose and schedule of gemcitabine (1000 mg/m 2 days 1 and 8) and docetaxel (40 mg/m 2 days 1 and 8) is currently being tested in a randomized phase III clinical trial led by investigators at Dartmouth and compared with the combination of carboplatin and docetaxel. 5 This study is powered to show equivalence between the platinum and non-platinum-based chemotherapy doublets. Preliminary reports indicate that the survival is similar between these doublets but that differences in the toxicity profiles exist. 5 Non-platinum-based chemotherapy produces similar outcomes to platinum-based chemotherapy. Rational application of specific chemotherapy doublets to specific patients may eventually provide an important advance. The current study does not provide definite evidence of pharmacogenomic profiling using the examined polymorphisms to select patients for non-platinum-based chemotherapy. Although the findings of this study are limited by the sample size, it appears that additional pharmacogenomic markers may need to be identified for helping clinicians choose between firstline use of platinum or non-platinum doublets. 
